Dermatitis News and Research

Latest Dermatitis News and Research

Mylan acquires two dermatological drugs from Valeant

Mylan Inc. today announced that it has successfully completed the acquisition of two dermatological products from Valeant Pharmaceuticals.

6 Feb 2012

GSK voluntarily pauses enrollment in GSK2251052 clinical trials for cUTI

Anacor Pharmaceuticals announced today that its partner GlaxoSmithKline has voluntarily paused enrollment in its current clinical trials of GSK2251052 due to a recently identified microbiological finding in a small number of patients in the Phase 2b trial of GSK '052 for the treatment of complicated urinary tract infections (cUTI).

6 Feb 2012

Oxygen Biotherapeutics to commence study to determine efficacy of Dermacyte in relieving Histamine induced pruritus

Oxygen Biotherapeutics, Inc. has announced that enrollment for the company’s first dermatological study will begin later this month at St. John’s Medical College Hospital in Bangalore, India. The company received formal approval from the hospital’s Ethics Review Board in December. This study is the first of a series of trials scheduled for 2012 to explore the efficacy of Dermacyte to treat a variety of dermatological conditions, such as allergic contact dermatitis, psoriasis and acne.

9 Jan 2012

Enrollment complete in two Anacor's tavaborole Phase 3 trials on onychomycosis

Anacor Pharmaceuticals announced today that it has completed the enrollment of approximately 600 patients in the second of its two Phase 3 trials of tavaborole, a topical anti-fungal product candidate for the treatment of onychomycosis, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.

23 Dec 2011

FDA Commissioner revokes approval of Genentech's Avastin for treatment of mBC

Genentech, a member of the Roche Group, announced today that the FDA Commissioner is revoking the approval of Avastin (bevacizumab) for the treatment of mBC in the United States.

18 Nov 2011

Provectus presents data from PV-10 Phase 2 study at 2011 International Melanoma Congress

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that data and study design features on PV-10 for metastatic melanoma were presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting, in Tampa, Florida.

14 Nov 2011

Conference highlights advances in evidence-based integrative therapies for cancer

Today the Society for Integrative Oncology highlighted top research findings presented at the Eighth International Conference this week in Cleveland, Ohio. More than 80 abstracts will be presented at the annual meeting, which will be keynoted by National Institutes of Health Director, Francis Collins, MD, PhD.

11 Nov 2011

Provectus announces data from Phase 2 PV-10 metastatic melanoma study

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting.

11 Nov 2011

Enrollment complete in Anacor's first of two tavaborole Phase 3 trials for onychomycosis

Anacor Pharmaceuticals announced today that it has completed enrollment in the first of two Phase 3 trials of tavaborole (formerly known as AN2690), a topical anti-fungal product candidate for the treatment of onychomycosis.

9 Nov 2011

KYTHERA presents long-term results from ATX-101 Phase 2 study at ASDS 2011

KYTHERA Biopharmaceuticals, Inc., a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, presented results from a long-term follow up study assessing persistence of efficacy and post-treatment safety of ATX-101, a first-in-class, injectable drug that is under investigation for the reduction of submental fat.

7 Nov 2011

Study evaluates availability of information about cosmetic ingredients for celiac patients

The lack of readily available information about cosmetic ingredients may cause patients with celiac disease who use lip, facial or body products to unknowingly expose themselves to gluten—an ingredient they need to avoid, according to the results of a new study unveiled today at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC.

1 Nov 2011

Thanksgiving Day tips for people with food allergies

Thanksgiving is about family, food and travel. And for the millions of Americans with allergies or asthma, it's about navigating a minefield of triggers, from the pumpkin pie to the dusty guest bedroom. "A number of holiday-related triggers can make people sneeze, wheeze or, in the case of food allergies, have a more serious reaction," said allergist Dr. Myron Zitt, past president of the Allergy, Asthma and Immunology (ACAAI). "But by planning ahead, the day can go smoothly for people with allergies or asthma."

29 Oct 2011

Lifestyle factors and nutritional patterns reduce early causes of childhood allergy

Today, about one in four European children suffer from allergy, which makes this disease the non-infectious epidemic of the 21st century. Evidence suggests that lifestyle factors and nutritional patterns, such as breastfeeding, help to reduce the early symptoms of allergy.

15 Oct 2011

UCSF, Anacor to discover and optimize novel oxaboroles as antimalarial drugs

Anacor Pharmaceuticals announced today that the University of California San Francisco (UCSF) has been awarded $718,136 in funding from the National Institutes of Health (NIH) to discover and optimize novel oxaboroles as antimalarial drugs in collaboration with Anacor Pharmaceuticals. The NIH grant provides support for the period beginning September 30, 2011 and ending September 29, 2012.

12 Oct 2011

Creabilis receives $20 million in Series B funding

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain, has raised €15 million ($20 million) in a Series B funding round led by Abbott Biotech Ventures.

4 Oct 2011

Six sneaky triggers of allergies and asthma

Halloween can be a frightful time for parents of kids with allergies and asthma. Nut-filled candy isn't the only bogeyman that can ruin the fun. Allergy and asthma triggers can hide in other, unexpected places, too, from dusty costumes to leering jack-o-lanterns.

30 Sep 2011

Invida, Sinclair IS launch two dermatology products in seven Asia-Pacific markets

Sinclair IS Pharma Plc, the international specialty pharmaceutical company, and Invida Holdings Private Limited, a leader in the commercialisation of specialty biopharmaceutical and healthcare products throughout Asia Pacific, announce that their partnership has already led to the launch of two Sinclair IS dermatology products in seven Asia-Pacific markets.

30 Sep 2011

Laurantis Pharma's Lymfactin rebuilds lymphatic vessels in pre-clinical animal models

Laurantis Pharma, a privately held biotechnology company based in Finland, today announced that Lymfactin, adenoviral VEGF-C growth factor therapy, was successful in rebuilding lymphatic vessels in pre-clinical animal models.

26 Sep 2011

GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052

Anacor Pharmaceuticals announced today that its partner, GlaxoSmithKline (GSK), has been awarded a contract with the U.S. Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) to support the ongoing development of GSK2251052 (GSK '052, formerly AN3665), a novel boron-based Gram-negative systemic antibiotic discovered by Anacor.

7 Sep 2011

Perrigo's ANDA for Ketoconazole Foam, 2% receives final FDA approval to treat seborrheic dermatitis

Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Ketoconazole Foam, 2%, the generic version of Extina Ketoconazole Foam, 2%.

31 Aug 2011

Dermatitis News and Research

Latest Dermatitis News and Research

Mylan acquires two dermatological drugs from Valeant

GSK voluntarily pauses enrollment in GSK2251052 clinical trials for cUTI

Oxygen Biotherapeutics to commence study to determine efficacy of Dermacyte in relieving Histamine induced pruritus

Enrollment complete in two Anacor's tavaborole Phase 3 trials on onychomycosis

FDA Commissioner revokes approval of Genentech's Avastin for treatment of mBC

Provectus presents data from PV-10 Phase 2 study at 2011 International Melanoma Congress

Conference highlights advances in evidence-based integrative therapies for cancer

Provectus announces data from Phase 2 PV-10 metastatic melanoma study

Enrollment complete in Anacor's first of two tavaborole Phase 3 trials for onychomycosis

KYTHERA presents long-term results from ATX-101 Phase 2 study at ASDS 2011

Study evaluates availability of information about cosmetic ingredients for celiac patients

Thanksgiving Day tips for people with food allergies

Lifestyle factors and nutritional patterns reduce early causes of childhood allergy

UCSF, Anacor to discover and optimize novel oxaboroles as antimalarial drugs

Creabilis receives $20 million in Series B funding

Six sneaky triggers of allergies and asthma

Invida, Sinclair IS launch two dermatology products in seven Asia-Pacific markets

Laurantis Pharma's Lymfactin rebuilds lymphatic vessels in pre-clinical animal models

GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052

Perrigo's ANDA for Ketoconazole Foam, 2% receives final FDA approval to treat seborrheic dermatitis

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Dermatitis News and Research

Latest Dermatitis News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in